



**edap tms**  
Bringing New Horizons to Therapy

## **EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024**

Oct 24, 2024

*Company to host conference call and webcast on Thursday, November 7<sup>th</sup> at 8:30am EDT*

LYON, France, October 24, 2024 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2024, before the markets open on Thursday, November 7<sup>th</sup>, 2024.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

### **Call Details:**

Date: Thursday, November 7<sup>th</sup>

Time: 8:30 am EDT

Domestic: 1-800-445-7795

International: 1-785-424-1699

Passcode: EDAP

Webcast: [https://viaavid.webcasts.com/starthere.jsp?ej=1691338&tp\\_key=a13da04d10](https://viaavid.webcasts.com/starthere.jsp?ej=1691338&tp_key=a13da04d10)

### **About EDAP TMS SA**

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, [us.hifu-prostate.com](http://us.hifu-prostate.com) and [www.focalone.com](http://www.focalone.com).

### **Company Contact**

Blandine Confort  
Investor Relations / Legal Affairs  
EDAP TMS SA  
+33 4 72 15 31 50  
[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

### **Investor Contact**

John Fraunces  
LifeSci Advisors, LLC  
(917) 355-2395  
[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)